MDD stands for major depressive disorder, a common and impairing mood disorder characterized by persistent depressive episodes and reduced functioning. It is associated with substantial mental health burden across age groups.
Helus completed Phase 3 enrollment for HLP003 in depression; data due Q4 2026. Compass is on track for COMP360's NDA, and an ayahuasca ingredient showed promise in a phase 2a trial.
A secondary analysis of the OPTIMUM trial found that higher doses of bupropion and prior fall history significantly increase fall risk in older adults with treatment-resistant depression receiving antidepressant augmentation.
Systematic review identifies shared molecular signatures in brain and blood for major depressive disorder, while separate study finds brain-enriched circRNA can predict SSRI treatment response.
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
The FDA has approved BYSANTI (milsaperidone), a new chemical entity for treating bipolar I disorder and schizophrenia in adults. The drug is Vanda's second approval in less than two months and is expected to launch in Q3 2026.
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07629050 |
Functional Electrical Stimulation for MDD |
NOT_YET_RECRUITING | NA |
| NCT07572526 |
tDCS: Sleep to Mood in Depression (S2M-D) |
RECRUITING | NA |
| NCT07562191 |
Inhaled DMT for Major Depressive Disorder |
RECRUITING | PHASE2 |
| NCT07439744 |
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status |
RECRUITING | NA |
| NCT07422844 |
Dynamic Network Response to TMS Treatment |
RECRUITING | |
| NCT07269964 |
At-Home tDCS as Maintenance Therapy |
RECRUITING | NA |
| NCT07111390 |
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) |
RECRUITING | NA |
| NCT06828887 |
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD |
RECRUITING | PHASE2 |
| NCT06699940 |
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents |
COMPLETED | |
| NCT06698666 |
Efficacy of Statins Among Major Depressive Disorder |
RECRUITING | PHASE3 |
